| Abstrakt: |
Background:Progressive heart failure is the cause of mortality for almost 25% of patients with cardiac sarcoidosis (CA). However, there are limited studies on the impact of heart failure (HF) on mortality, hospital length of stay (LOS), and total hospital charges for patients with cardiac sarcoidosis.Methods:Data were extracted from the National Inpatient Sample (NIS) 2016-2019 Database. The NIS was searched for hospitalizations for adult patients with cardiac sarcoidosis as the principal discharge diagnosis with and without different types of heart failure as secondary diagnosis using ICD-10 codes. Multivariate analysis via STATA was used to adjust for confounders.Results:6,560 patients were identified with a diagnosis of cardiac sarcoidosis. Only 0.08% of patients with heart failure were identified with a diagnosis of cardiac sarcoidosis, of which 15.8% had systolic HF, 3.7% diastolic had HF, and 14% had combined systolic and diastolic HF. There were more males than females (60.0% vs. 40.0 %, p<0.01).Mortality was increased for combined systolic and diastolic HF (OR 1.98, p<0.04). LOS was increased for patients with any type of HF(+2.48 days, <0.001), systolic heart failure (+2.14 days, p<0.017), combined systolic and diastolic HF (+1.96 days, p<0.010). Total hospital charges were increased with any type of HF ($44,214.43, p<0.004), and systolic heart failure ($58,298.90, p<0.015). Interestingly, patients with cardiac sarcoidosis did not have increased mortality with all types of HF(OR 1.04, p=0.928), systolic HF (OR 0.98, p=0.973), diastolic HF (OR 0.35, p=0.179), and combined systolic and diastolic HF (OR 1.34 experienced a 51% increased odds of mortality (OR 1.51, 95%CI 1.41-1.62, p<0.01), a longer LOS with a mean difference of 1.4 days (95%CI, 1.16-1.57, p<0.01), and a more costly overall hospitalization with a mean difference of $12,841 (95%CI $9,705-$15,976, p<0.01).Conclusion:Cardiac sarcoidosis remains a widely under-recognized cause of HF hospitalizations in the United States. |
